Imricor Medical Systems (ASX:IMR) - Chair and CEO, Steve Wedan
Chair and CEO, Steve Wedan
Source: Imricor
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imricor Medical Systems (IMR) signs a sales distribution deal with Norway’s NordicNeuroLab
  • Headquartered in the United States, Imricor develops compatible devices for use in MRI-guided cardiac catheter ablation procedures
  • Under the deal, IMR will become a non-exclusive distributor of Nordic’s “InroomViewingDevice”, which is used in the magnet room of iCMR laboratories
  • Shares were down 2.86 per cent at $1.19 at market close on August 30

Imricor Medical Systems (IMR) has signed a sales deal with one of Norway’s leading makers of MRI-compatible in-room monitors, NordicNeuroLab.

Headquartered in the United States, Imricor develops compatible devices for use in MRI-guided cardiac catheter ablation procedures.

Under the agreement, IMR is set to become a non-exclusive distributor of Nordic’s “InroomViewingDevice”— a reportedly high-quality, 40-inch monitor designed for use in the magnet room of an iCMR laboratory.

Imricor Chair and CEO Steve Wedan commented on the arrangement.

“Imricor has two of these monitors installed in our own iCMR Design Centre, and many of our customers have also chosen these monitors for their iCMR labs,” he said.

“The agreement with NordicNeuroLab streamlines the sales process for all parties and strengthens the range of third-party iCMR lab equipment Imricor offers to its customers.”

NordicNeuroLab CEO Thomas Lie Omdahl said Nordic was excited to partner with IMR as the first company in the world to bring commercially viable and safe iCMR products to the catheter ablation market.

“The partnership with Imricor allows us to further expand the utilisation of certain functional MRI imaging peripherals, such as the InroomViewingDevice, to benefit more patients and clinicians worldwide,” Mr Omdahl said.

Imricor shares were 2.86 per cent in the red at $1.19 at market close on August 30.

IMR by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…